Food Trial to Evaluate the Kinetics of the Medical Foods SBD111 and SBD121 Persistence in Healthy Adults

April 25, 2025 updated by: Solarea Bio, Inc
This study is a randomized, open-label, trial in healthy volunteers. Trial participants will be given a medical food product (combination of probiotics and prebiotics) called SBD111 or SBD121 for seven days and microbial abundance in feces will be measured during that time and for four weeks following administration.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

This DMA persistence food trial provides critical complimentary data to the ongoing efficacy food trials of SBD111 and SBD121 medical foods. While the SBD111 and SBD121 medical food products have been tested in multiple preclinical studies, GLP-Toxicity studies in Rats, and ongoing safety and efficacy trials, no study has yet examined how quickly these DMAs become detectable/active in human stool samples or the rate they clear from human stool following treatment cessation. The data provided by this study could inform the interpretation efficacy trial data with regard to subject adherence.

Objectives The primary goal of this study is to evaluate the prevalence and persistence of SBD111 and SBD121 medical foods, two novel combinations of probiotics and prebiotic dietary fibers, over time in stool samples. We will determine the effect of these Defined Microbial Assemblages (DMAs) on fecal microbiota composition and functional potential, as well as the duration of SBD111 and SBD121 product persistence in the gastrointestinal tract. DMAs will be administered for 7 days, and stool samples will be collected during DMA administration and up to 28 days post DMA cessation for microbial DNA extraction. Fecal microbial DNA will be subjected to qPCR and high throughput shotgun sequencing to determine the presence and amount of DMA microbes that are present before, during, and after DMA administration. We will also use the resulting shotgun sequencing data to determine whether any taxonomic shifts or functional changes occur in response to DMA administration and/or cessation. Finally, as an exploratory measure, we will attempt to isolate live DMA microbes from participants' fecal samples using microbiological techniques.

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Massachusetts
      • Waltham, Massachusetts, United States, 02453-8400
        • Solarea Bio Inc

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  1. Provide written informed consent.
  2. Stated availability throughout entire study period and willingness to fulfill all details of the protocol.
  3. Age 18-64 years.
  4. Be in general good health as determined by a screening evaluation within 30 days of the first dose of SBD111 or SBD121.
  5. Willing to comply with protocol and report on compliance and side effects during study period.
  6. Body Mass Index between 18.5 and 35 kg/m2.

Exclusion Criteria:

  1. Are currently taking probiotic or prebiotic supplements or have taken them in the past 30 days.
  2. Unwilling to avoid probiotics/prebiotics supplements for the duration of the study.
  3. Known or suspected allergies to probiotics, maltodextrin, or berries.
  4. Received oral or parenteral antibiotics within 3 months of enrollment or prescribed antibiotics on the day of enrollment.
  5. Major surgery on the intestines or endoscopy within last 3 months.
  6. Current smoker.
  7. History of drug and/or alcohol abuse at the time of enrollment.
  8. Presence of any of the following:
  9. Abnormal vital signs or clinically significant systems abnormalities based on screening questionnaire.

  10. Indwelling catheter or implanted hardware/prosthetic device or feeding tube.

    a. Excluding joint replacements

  11. Febrile illness (oral temperature >37 degrees Celsius) or one or more episodes of diarrhea within 72 hours of baseline (first dose of study article).
  12. Active bowel leak, acute abdomen, colitis, or active GI disease or history of gastric or intestinal dysmotility, slowed transit time, variable small intestinal permeability, pancreatitis, or inflammatory bowel disease.
  13. History of Hepatitis B or Hepatitis C infections, cirrhosis, or chronic liver disease.
  14. Underlying structural heart disease or previous history of endocarditis or valve replacement.
  15. Immunosuppression including HIV positive, solid organ or stem cell transplant recipient, receiving any oral or parenteral immunosuppressive therapy.
  16. History of Celiac disease.
  17. History of cancer.
  18. Excluding non-melanoma skin cancers or cancer more than 10 years ago.
  19. History of autoimmune disease and taking any immunosuppressant drugs.
  20. Active TB.
  21. Women only - pregnant, planning on becoming pregnant within the next 2 months, breastfeeding, positive urine pregnancy test within 24 hours of first dose of DMA.
  22. Participants may be excluded if, in the investigator's opinion, there is evidence of cognitive impairment or dementia which is sufficient to interfere with informed consent or adherence to the study protocol. Four questions will be asked during the informed consent process to confirm participant's understanding and ability to comply.
  23. Any other condition that in the opinion of the investigator would jeopardize the safety or rights of the volunteer participating in the study or would make it unlikely the volunteer could complete the study.
  24. Bowel movement frequency less than one per 36-hour period.
  25. If the subject has been in a recent experimental trial, these must have been completed not less than 60 days prior to this study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Synbiotic Medical Food SBD111
Probiotic comprised of three lactic acid bacteria and one yeast
Other: SBD111 Probiotic Medical Food
Medical food comprised of probiotics and prebiotic fibers
Experimental: Synbiotic Medical Food SBD121
Probiotic comprised of three lactic acid bacteria and one bacillus
Other: SBD121 Probiotic Medical Food
Probiotic medical food comprised of three lactic acid bacteria and one bacillus

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Persistence of SBD111 and SBD121 microbes in fecal samples
Time Frame: 5 weeks
DNA isolated from fecal swabs will be used to determine the persistence of SBD111 and SBD121 microbes in stool samples up to 28 days following twice-daily oral administration of SBD111 or SBD121 to healthy adults.
5 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Microbial Community Structure Changes
Time Frame: 5 weeks
Using metagenomic sequencing, we will assess microbial community structural and functional changes that occur during and up to 28 days following twice-daily oral administration of SBD111 or SBD121 to healthy adults. This will be done via sequence assessment of microbiota taxonomies and functional genes.
5 weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Microbe Viability
Time Frame: 2 weeks
From frozen fecal samples we will assess the viability of SBD111 and SBD121 microbes in fecal samples after 0, 7, and 14 days of oral administration using standard microbiological plating techniques.
2 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Solarea Bio, Inc

Investigators

  • Principal Investigator: Alicia E Ballok, PhD, Solarea Bio, Inc

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 14, 2024

Primary Completion (Estimated)

May 23, 2025

Study Completion (Estimated)

June 28, 2025

Study Registration Dates

First Submitted

September 19, 2024

First Submitted That Met QC Criteria

September 23, 2024

First Posted (Actual)

September 26, 2024

Study Record Updates

Last Update Posted (Actual)

April 27, 2025

Last Update Submitted That Met QC Criteria

April 25, 2025

Last Verified

April 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Pro00078728

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

no plan

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Bone Density

Clinical Trials on SBD111 Probiotic Medical Food

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe